Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S. FDA Counts 62 Deaths That Could Be Tied To Chinese Heparin

This article was originally published in PharmAsia News

Executive Summary

The U.S. FDA says it has received 62 reports of deaths that could be tied to Chinese-produced heparin, more than triple the numbers announced previously. The 62 died within the past 15 months of allergic reactions or low blood pressure, symptoms involved with contaminated heparin. The FDA cautions the heparin may not be the cause of death in all cases. Baxter International recalled most of the product in February, but the drug was produced from basic supplies also shipped to other makers of the drug, such as APP Pharmaceuticals, which said its users were not among the 62 listed by the FDA. (Click here for more

You may also be interested in...

U.S. FDA Triples Estimate On Deaths Following Allergic Reaction To Blood Thinner Heparin

BEIJING - U.S. FDA last week issued a sharply higher estimate on the number of deaths that have occurred in patients who suffered allergic reactions to the blood thinner heparin

Medtronic/Tandem Patent Agreement Paves Way For Diabetes Product Development

Tandem Diabetes Care and Medtronic have signed a patent cross-license agreement that paves the way for joint development of future diabetes products and services while avoiding potential legal disagreements.

GDUFA Sees First-Ever Fee Spending Decrease

Thanks in part to budget authority bump, US FDA’s generic user fee revenue spending dropped in FY 2019, and hiring problems lead to an FTE decrease. The useable GDUFA carryover balance also increased in conjunction with the user fee revenue spending reduction, from $158.7m available at the end of FY 2018 to $199.2m at the end of FY 2019.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts